Digest Network Come funziona
Network
/
Società
In
Non verificato

InnoCare Pharma

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaOncologiaSalute

24 comunicati stampa

Guarda tutti i comunicati
19/08/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Telefonia e Varie
Mercato azionario
InnoCare Releases 2025 Interim Results and Business Highlights
Fonte
InnoCare Pharma
Emittente
Business Wire
1.00
0
04/07/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China
Fonte
InnoCare Pharma
Emittente
Business Wire
1.00
0
13/06/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Data of InnoCare’s Robust Hemato-Oncology Pipelines Presented at the European Hematology Association (EHA) 2025 Congress
Fonte
InnoCare Pharma
Emittente
Business Wire
1.00
0
02/06/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Eventi
Industria
Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2025 ASCO Annual Meeting
Fonte
InnoCare Pharma
Emittente
Business Wire
1.00
0
29/05/2025
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Industria
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor Mesutoclax for Myelodysplastic Syndromes in China
Fonte
InnoCare Pharma
Emittente
Business Wire
1.00
0
21/05/2025
Industria
Biotecnologia
Farmaceutica
Salute
Oncologia
InnoCare Announces the Approval of Minjuvi® (Tafasitamab) in Combination with Lenalidomide for the treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
Fonte
InnoCare Pharma
Emittente
Business Wire
1.00
0
16/05/2025
Industria
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China
Fonte
InnoCare Pharma
Emittente
Business Wire
1.00
0
12/05/2025
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
InnoCare’s Mesutoclax Receives Breakthrough Therapy Designation from China’s NMPA
Fonte
InnoCare Pharma
Emittente
Business Wire
1.00
0
02/05/2025
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
InnoCare’s Zurletrectinib Receives Priority Review from China’s NMPA
Fonte
InnoCare Pharma
Emittente
Business Wire
1.00
0
25/04/2025
Industria
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
InnoCare Announces Approval of Orelabrutinib for the First-line Treatment of CLL/SLL in China
Fonte
InnoCare Pharma
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0